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Docetaxel-loaded sustained-release preparation based on 2-Hydroxyethyl methacrylate
(HEMA) and Methyl methacrylate (MMA) cross-linked copolymer (P(HEMA-co-MMA)) was
prepared to examine the potential use for preventing posterior capsule opacification (PCO).
The preparations were prepared by polymerizing the mixture of HEMA, MMA, cross-linking
agent (EGDMA), initiator (AIBN) and docetaxel. The influence factors and mechanism of
drug release were studied in the experiments. FT-IR, X-RD and SEM methods were used to
characterize the polymer (P(HEMA-co-MMA)) and docetaxel-loaded sustained-release
preparations. Biocompatibility of P(HEMA-co-MMA) and in-vitro effect of docetaxel-loaded
sustained-release preparations were also evaluated. The results showed that docetaxel
could release sustainedly from these preparations prepared by cross-linking polymeriza-
tion. And the release rate could be accelerated by increasing the MMA ratio or EGDMA ratio
of the polymer. Release mechanism of docetaxel fitted the Higuchi model well. The results
of IR and X-RD showed that only a hydrogen bond was formed between docetaxel and
P(HEMA-co-MMA). Docetaxel dispersed in P(HEMA-co-MMA) in amorphous form. The
elution test showed that P(HEMA-co-MMA) had good biocompatibility and the in-vitro
pharmacodynamics study proved that docetaxel could release stably from the prepara-
tions and inhibit HLECs’ proliferation. The docetaxel-loaded sustained-release prepara-
tions proved to be a promising therapy for preventing PCO. These results also lay a
theoretical and experimental foundation for the future.
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a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 2 5 2e2 6 0 2531. Introduction 2. Materials and methodsBy far, cataracts are the most common cause of low visual
acuity. It is effectively treated by surgical procedure i.e.
Phacoemulsification or Extra-Capsular Cataract Extraction
(ECCE). However, the incidence of Posterior Capsule Opacifi-
cation (PCO) is up to 50% in adults and 100% in children [1e3],
and it is a routine complication. It is caused by the prolifera-
tion and migration of the residual lens epithelial cells (LECs)
left during the cataract surgery. As soon as PCO occurs,
Nd:YAG laser must be used to treat the complication. But
additional surgery involves additional expenses and mort-
gages. Moreover, this procedure may also cause rhegmatoge-
nous retinal detachment or endophthalmitis. What’s more, it
is somewhat difficult to treat dense capsular opacification
after operation for congenital cataract by Nd:YAG laser in in-
fancy [1]. Thus, it is necessary to develop a non-surgical
method to prevent PCO. Pharmacologic agents have been
studied to prevent PCO for their inexpensive, convenient and
digestible.
Many drugs such as Genipin, Proteasome inhibitors,
Lithium, Mitomycin C, 5-FU and Diclofenac [4e18] display a
strong inhibitory effect on LECs’ proliferation as well as their
serious toxicity to other intraocular structure. In order to
reduce the toxicity of pharmacologic agents, some re-
searchers irrigated the capsular bag for a few minutes with
pharmacologic agents after phacoemulsification [12,19].
Maloof AJ et al. developed a Sealed Capsule Irrigation (SCI)
device [3,9,20]. Weidmann A and Xie L et al. developed sus-
tained release preparations such as microspheres, microcap-
sules [10,21,22], liposomes [23,24] and drug-surface-modified
intraocular lenses [25e27]. All of these methods could reduce
the incidence of PCO, but they all had their own defects
[28e30].
Hydrophilicity acrylic ester made from HEMA and MMA
by chemical cross-linking copolymerization is a kind of
non-degradation material, which has been widely used in
medicine. Due to such properties as non-toxicity, non-
antigen and satisfactory biocompatibility, it has been used
as the materials of many medical products such as intra-
ocular lenses [31e34], capsular tension rings [35e39], soft
contact lenses [40] and artificial skin [41]. It has also been
studied commonly as an ophthalmological carrier of drugs
such as pilocarpine [42], Mitomycin C [43,44] and 5-FU
[45]. Consequently, HEMA and MMA cross-linked copol-
ymer P(HEMA-co-MMA) was used as a carrier in this
research.
In our previous research [46], docetaxel was found to be a
strong inhibitor of HLECs’ proliferation (IC50: 16.48 ng/ml,
72 h). It could inhibit and delay G2/M phase transition of
HLECs, induce HLECs’ early apoptosis, and decrease the
expression of bcl-2 protein. Therefore, docetaxel was chosen
as the model drug in this research.
P(HEMA-co-MMA) with docetaxel was prepared and sha-
ped into a ring, which could be inserted into ocular when ECCE
surgery was carried out. After the drug was released, it could
still play a role in supporting the capsular bag and preventing
the capsular bag from shrinking.2.1. Materials
Methyl methacrylate (MMA) and azobis-iso-butrylonitrile
(AIBN) were purchased from Tianjin Damao Chemical Re-
agent Factory; 2-hydroxyethyl methacrylate (HEMA) was
purchased from Guangzhou Zhenlin Trading Co., LTD
(China); ethylene glycol dimethacrylate (EGDMA) was pro-
vided by Guangzhou Shuangjian Trading Co., LTD (China);
docetaxel was purchased from Peking Xinze Technology Co.,
LTD (China); Dulbecco modified Eagle’s medium (DMEM) and
trypsin were purchased from Gibco Co. (USA); fetal bovine
serum (FBS) was obtained from Hangzhou Sijiqing Biological
Engineering Co., LTD (China); and 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT) was purchased
from Sigma Chemical Co. (USA). Mouse fibroblast cell line (L-
929) was purchased from the Center of Experiment Animal
of Sun Yat-sen University (Guangzhou, China); and human
lens epithelial cells (HLECs, SRA01/04）were purchased
from Cell Resource Center of Peking Union Medical College
(Beijing, China). All the other chemicals were of analytical
grade.2.2. Synthesis methods
Docetaxel-loaded sustained-release preparations were syn-
thesized by free radical solution polymerization method.
Firstly, the monomer of HEMA, MMA and the cross-linker
EGDMA were mixed together. Then the mixture was
degassed by bubbling nitrogen for 30 min after AIBN initiator
and docetaxel were added to it. Secondly, the solution was
poured into a homemade mold. And finally, the polymeriza-
tion reaction was performed in an oven at 60 C for 24 h.
Docetaxel-loaded sustained-release preparations with
different MMA/HEMA ratios (mol/mol ¼ 1:9, 1.5:8.5, 2:8, 2.5:7.5
and 3:7) were prepared respectively. The pure P(HEMA-co-
MMA) was synthesized without docetaxel.2.3. Study on in-vitro drug release
Drug release experiments were conducted as follows: the
docetaxel-loaded sustained-release preparations were put
into containers containing 3 ml pH 7.4 phosphate buffered
saline (PBS). The containers were shaken in a horizontally
reciprocating shaker at 37 C (0.5 C). After being shaken for 1
day, the docetaxel-loaded sustained-release preparations
were then transferred into other containers containing 3 ml
fresh PBS respectively. Transfers were taken at 1d, 2d.16d,
18d.30d and 35d. Samples were detected by high-
performance liquid chromatography (HPLC) and the HPLC
methods were as follows: 50 mL liquids were injected for
analysis. The mobile phase was acetonitrile/water (which
equals 55/45), column temperature was 35 C, flow rate was
1 ml/min, and wavelength was 232 nm.
The drug release behavior of docetaxel-loaded sustained-
release preparations with different MMA/HEMA ratios (mol/
Fig. 1 e Effects of different MMA/HEMA ratios on in-vitro
docetaxel release (0.3% EGDMA) (n [ 3).
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 2 5 2e2 6 0254mol¼ 1:9, 1.5:8.5, 2:8, 2.5:7.5 and 3:7) were studied by the same
methods described above respectively.
2.4. Swelling ratio
The swelling properties of pure P(HEMA-co-MMA) were
determined gravimetrically. Firstly the samples were placed
in 5 ml DI water at room temperature. When their weight was
stable after removing excesswater, the sampleswereweighed
on an electronic balance (92SM-202A, Precisa). And the sam-
ples were weighed on an electronic balance again after being
dried by a drying vacuum oven at 60 C for 48 h. The swelling
ratio was calculated by the following equation:
Swelling ratio ð%Þ ¼ ðWw WdÞ=Wd  100;
Ww represents the wet weight of the sample; Wd represents
the dry weight of the sample.
2.5. Characterization of docetaxel-loaded sustained-
release preparations
The IR spectra of the samples were recorded on an FTIR
spectrometer (EQUINOX 55, Bruker, German) using KBr discs.
The spectra were recorded from 4000 cm1 to 500 cm1.
Powder X-ray diffraction measurements were carried out
on D/Max-IIIA (Rigaku, Japan) with Cu, 35 KV and 25 mA. The
DS/SS was 1. The analysis was performed with 2q varying
from 3 to 60 at a scan speed of 12/min.
The microstructure of samples was studied with Scanning
Electron Microscopes (JSM-6330F, Jeol, Japan). Samples were
cracked in liquid nitrogen with 15 kV accelerating voltages.
2.6. Biocompatibility studies of P(HEMA-co-MMA)
According to the national standard GB/T 16886, the cytotox-
icity of one-month leaching liquor of homemade P(HEMA-co-
MMA) (MMAmol/HEMAmol ¼ 9:1, 8.5:1.5, 8:2, 7.5:2.5, 7:3) was
evaluated on L-929 cells. Phenol (6.3%) and culture medium
(DMEM with 20% FBS, DMEM (20)) were used as positive and
negative control groups respectively. Cells with samples were
incubated together in a 96-well plate for 48 h. Then the sam-
ples were removed and 20 ml MTT solution (5 mg/ml, final
concentration) was added. 4 h later, the MTT solution was
removed and 150 ml DMSOwas added to dissolve the blueMTT
formazan precipitate. The absorbance of each well (OD) was
measured at 490 nm with an ELISA Reader (Elx800, BIO-TEK,
USA). The viability was calculated from the absorbance ra-
tios of the sample group to the control group.
2.7. Studies on in-vitro pharmacodynamics
HLECswerecultured ina24-well plate (1*104 cells/ml)at37 C for
24 h, then the medium was changed and the docetaxel-loaded
sustained-release preparations were hung in the well of the
plate by a stainless steel wire in order that the preparations
could be immersed in the culture solutionwithout touching the
cells. Then after incubated at 37 C for 2 days, the docetaxel-
loaded sustained-release preparations were transferred into
another24-well plate containingHLECs.Transferswere takenat
2d, 4d,., 20d, respectively. The concentration of docetaxel inDMEM (20) was then determined by HPLC. HPLCmethods were
the same as above. The in-vitro effect of inhibiting HLECs pro-
liferation by docetaxel-loaded sustained-release preparations
wasevaluated throughMTTassay inthispart. Firstly, 200mlMTT
solution (5mg/ml, final concentration)was added to the 96-well
plate for each well and the cells were incubated continually for
4 h. After the MTT solution was removed, MTT formazan pre-
cipitate was dissolved in 750 ml DMSO. The absorbance of each
wellwasmeasuredat 490nmwithanELISAReader (Elx800,BIO-
TEK, USA). The cell viability was calculated by the absorbance
ratios of the sample group to the control group.3. Results and discussion
3.1. Synthesis methods
The docetaxel-loaded sustained-release preparations and the
pure P(HEMA-co-MMA) were successfully synthesized in
cross-linking polymerization procedure. HEMA and MMA are
monomers used to synthesize pHEMA, pMMA and P(HEMA-
co-MMA). EGDMA is commonly used as a cross-linking agent
in synthesizing P(HEMA-co-MMA).
There are always two methods for loading drugs into
P(HEMA-co-MMA). One is that the drug solution is absorbed
into the pure polymer due to different distribution coefficients
between polymer and water [47,48]. The other is dissolving or
suspending the drug into the mixture of monomer at the
beginning of the polymerization procedure [42,49]. Drug usu-
ally releases very fast from the preparations made by the first
method [48], while temperature-sensitive drugs are not suit-
able to be used by the second method. For the purpose of
obtaining sustained-release preparations, the second method
was employed in our research.
3.2. Release mechanism investigation
With a constant amount of cross-linker, the release rate of
docetaxel could be retarded by increasing the ratio of MMA/
Table 1 e Fitting equations for docetaxel release profiles
from P(HEMA-co-MMA) with different MMA/HEMA ratios.
No. MMA/
HEMA
Equation Fitting equation r2
a 1:9 Zero-order kinetics y ¼ 0.0200x þ 0.2737 0.8333
First-order kinetics y ¼ 0.0209x  0.1037 0.9492
Higuchi model y ¼ 0.1522x þ 0.0207 0.9500
Peppas equation y ¼ 0.5979x  0.9117 0.9415
b 2.5:8.5 Zero-order kinetics y ¼ 0.0172x þ 0.226 0.8553
First-order kinetics y ¼ 0.0144x  0.0933 0.9367
Higuchi model y ¼ 0.1296x þ 0.0123 0.9618
Peppas equation y ¼ 0.5795x  0.9654 0.9605
c 2:8 Zero-order kinetics y ¼ 0.0099x þ 0.1313 0.9176
First-order kinetics y ¼ 0.0056x  0.0591 0.9430
Higuchi model y ¼ 0.0628x þ 0.0432 0.9858
Peppas equation y ¼ 0.4225x  1.0348 0.9802
d 2.5:7.5 Zero-order kinetics y ¼ 0.0068x þ 0.09 0.8853
First-order kinetics y ¼ 0.0036x  0.0397 0.9090
Higuchi model y ¼ 0.0509x þ 0.0069 0.9774
Peppas equation y ¼ 0.5493x  1.3316 0.9719
e 3:7 Zero-order kinetics y ¼ 0.0021x þ 0.0368 0.8522
First-order kinetics y ¼ 0.001x  0.0163 0.8593
Higuchi model y ¼ 0.0133x þ 0.0179 0.9383
Peppas equation y ¼ 0.374x  1.5906 0.9330
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docetaxel decreased from 38.5% to 2.0% as the MMA/HEMA
ratio increased from 1:9 to 3:7. On the twentieth day, there are
about three-quarters of docetaxel released from the
sustained-release preparations with an MMA/HEMA ratio of
1:9, but less than 10% docetaxel was released from the
sustained-release preparations with an MMA/HEMA ratio of
3:7 (Fig. 2).
Zero-order kinetics, first-order kinetics, the Higuchi model
and Peppas equation were used to investigate docetaxel
release mechanism from the sustained-release preparations.
According to the correlation coefficient (r2), the fitting results
showed that the release curves of docetaxel-loaded sustained-
release preparations with MMA/HEMA ratios of 1:9, 1.5:8.5 and
2.5:7.5 fitted the Higuchi model (Table 1a, b, d) very well. Both
the Higuchi model and Peppas equation fitted the release
curves of the preparations with MMA/HEMA ratios of 2:8 and
3:7 (Table 1c, e) and the statistical analysis results indicated
that there were no statistical significance ( p > 0.1) of the
ycalculation in the twomodels. The drug release rate constant (k)
calculated from the Higuchi model showed a linear relation-
ship with MMA/HEMA ratio (R). The linear equation was
k¼0.4457Rþ 0.1976, r2 ¼ 0.9452 ( p< 0.01), which indicated a
negative correlation between k and R.
The release behavior of docetaxel-loaded sustained-
release preparations in PBS (pH 7.4) was shown in Fig. 3. The
release rate gradually slowed down with an initial burst
release in the first five days. The concentration of docetaxel on
the first day was 3e4 times higher than that on the thirtieth
day especially. What’s more, the concentrations of docetaxel
in pH 7.4 PBS were much higher than the IC50 of docetaxel at
72 h at all release times, which indicated that the concentra-
tion of docetaxel released in vitro could maintain an effective
concentration.
Docetaxel-loaded sustained-release preparations with
different EGDMA ratio (v/v ¼ 0.3%, 1%, 2%, 6%, 8% and 10%) all
fitted the Higuchimodel verywell (Table 2a, b, c, d, e, f) and the
drug release rate constant (k) also showed a linear relationshipFig. 2 e In-vitro release of docetaxel-loaded sustained-
release preparations of different MMA/HEMA ratios at the
same time (n [ 3). (MMAmol/HEMAmol [ 1:9, 1.5:8.5, 2:8,
2.5:7.5 and 3:7).with EGDMA ratio (W ). The linear equation was
k ¼ 0.5225 W þ 0.1462, r2 ¼ 0.8640 ( p < 0.01).
Studies on in-vitro drug release could not reflect the in-vivo
drug release characteristics directly. But until now, there is no
practicable method specially used for intraocular drug release
studies. Therefore, according to the pertinent literature [49],
pH (about 7.4) and flow rate (2 w 3 ml/min) of the aqueous
humor, 3 ml PBS (pH 7.4) was adopted as a release medium
and the effects of different MMA/HEMA ratios and EGDMA
content on in-vitro release behavior of docetaxel from the
sustained-release preparations were studied.
The Higuchi model, which was the best fitting model,
suggested that the pure diffusion procedure was the main
drug release mechanism from these sustained-release prep-
arations [50,51]. According to the correlation equationsFig. 3 e The concentration diagram of in-vitro release of
docetaxel-loaded sustained-release preparations (n [ 3).
Table 2 e Fitting equations for docetaxel release profiles
from P(HEMA-co-MMA) with different EGDMA content.
No. EGDMA Equations Fitting equation r2
a 0.3% Zero-order kinetics y ¼ 0.0200x þ 0.2737 0.8333
First-order kinetics y ¼ 0.0209x  0.1037 0.9492
Higuchi model y ¼ 0.1522x þ 0.0207 0.9500
Peppas equation y ¼ 0.5979x  0.9117 0.9415
b 1% Zero-order kinetics y ¼ 0.0173x þ 0.2183 0.8704
First-order kinetics y ¼ 0.0144x  0.0876 0.9482
Higuchi model y ¼ 0.1295x þ 0.0059 0.9694
Peppas equation y ¼ 0.5843x  0.9772 0.9612
c 2% Zero-order kinetics y ¼ 0.0180x þ 0.1939 0.8838
First-order kinetics y ¼ 0.0147x  0.0725 0.9547
Higuchi model y ¼ 0.1340x  0.0246 0.9744
Peppas equation y ¼ 0.6250x  1.0389 0.9694
d 6% Zero-order kinetics y ¼ 0.0167x þ 0.1831 0.8977
First-order kinetics y ¼ 0.0130x  0.0702 0.9616
Higuchi model y ¼ 0.1243x  0.0188 0.9821
Peppas equation y ¼ 0.6036x  1.0425 0.9773
e 8% Zero-order kinetics y ¼ 0.0144x þ 0.1795 0.8752
First-order kinetics y ¼ 0.0103x  0.076 0.9352
Higuchi model y ¼ 0.1081x þ 0.0025 0.9723
Peppas equation y ¼ 0.5828x  1.057 0.9670
f 10% Zero-order kinetics y ¼ 0.0117x þ 0.1242 0.9005
First-order kinetics y ¼ 0.0072x  0.0521 0.9394
Higuchi model y ¼ 0.0867x  0.0164 0.9829
Peppas equation y ¼ 0.6112x  1.213 0.9774
Fig. 5 e FTIR spectra of docetaxel-loaded P(HEMA-co-MMA).
(a) Docetaxel (b) P(HEMA-co-MMA) (c) Mixture of docetaxel
and P(HEMA-co-MMA) (d) Docetaxel-loaded sustained-
release preparations.
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cific preparations with expectable release of docetaxel could
be designed and made. These correlation equations provided
a theoretical basis for designing and preparing the docetaxel-
loaded sustained-release preparations in the future.
3.3. Swelling ratio
The swelling ratios decreased as the MMA/HEMA ratios
increased. The swelling ratio of P(HEMA-co-MMA) was 55%
when theMMA/HEMA ratiowas 1:9; butwhen theMMA/HEMA
ratio increased to 3:7, the swelling ratio was only 33% (Fig. 4).
At the same time, the release of docetaxel from the sustained-
release preparations also decreased obviously. The reasonFig. 4 e Effects of different MMA/HEMA ratios of P(HEMA-
co-MMA) on the swelling ratio (n [ 3).was that there were many hydrophilic groups (eOH) in HEMA,
so when the MMA ratio in P(HEMA-co-MMA) increased, the
hydrophilicity decreased, which caused the drug release rate
to slow down. Cross-linker EGDMA could enhance the density
of P(HEMA-co-MMA), which also slowed down the drug
release rate [42].
3.4. Characterization of docetaxel-loaded sustained-
release preparations
The FT-IR spectrum (4000e500 cm1) was employed to analyze
the form of docetaxel entrapped in P(HEMA-co-MMA). The
stretching vibration of NeH at 3383 cm1 and 3335 cm1 and
the out-plane vibration of NeH at 708 cm1 (Amide Ⅴ band)
were the characteristic absorption band of docetaxel. How-
ever, these NeH absorption bands disappeared in P(HEMA-co-Fig. 6 e X-RD patterns of docetaxel-loaded P(HEMA-co-
MMA). (a) Docetaxel (b) P(HEMA-co-MMA) (c) Mixture of
docetaxel and P(HEMA-co-MMA) (d) Docetaxel-loaded
sustained-release preparations.
Fig. 7 e Scanning electron micrographs of the surface of P(HEMA-co-MMA). (a) Blank P(HEMA-co-MMA), MMA/
HEMA [ 1.5:8.5 (b) P(HEMA-co-MMA) with docetaxel, MMA/HEMA [ 1.5:8.5 (c) Blank P(HEMA-co-MMA), MMA/HEMA [ 3:7
(d) P(HEMA-co-MMA) with docetaxel, MMA/HEMA [ 3:7.
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existed in both docetaxel (Fig. 5a) and themixture of docetaxel
and P(HEMA-co-MMA) (Fig. 5c), but it also disappeared in FT-IR
spectra of docetaxel-loaded sustained-release preparations
(Fig. 5d). These results indicated that a hydrogen bonding
was formed by the interaction of the NeH of docetaxel and
the eOH or C]O groups of P(HEMA-co-MMA).
The hydrogen bond between docetaxel and P(HEMA-co-
MMA) could improve the compatibility between drug and
polymer. No other chemical bond was formed between them,
which suggested that the activity of docetaxel did not change.
The X-ray diffraction was employed to measure the crys-
talline property of docetaxel entrapped in P(HEMA-co-MMA).
The characteristic diffraction peaks of docetaxel were
2q ¼ 5.2, 9.8, 13.7, 15.7, 20.2. These characteristic diffrac-
tion peaks existed in both docetaxel and the mixture of
docetaxel and P(HEMA-co-MMA), but disappeared in
docetaxel-loaded sustained-release preparations (Fig. 6).Fig. 8 e Scanning electron micrographs of docetaxel-loaded sus
(MMAmol/HEMAmol [ 3:7). (a) Before release (b) After release.These results indicated that docetaxel dispersed in P(HEMA-
co-MMA) in the form of amorphism or molecule.
Scanning electron micrographs showed that there was no
grossdifferencebetweenpureP(HEMA-co-MMA)anddocetaxel-
loaded P(HEMA-co-MMA) (Fig. 7), which suggested that the in-
ternal structure of P(HEMA-co-MMA) did not change when
loaded with docetaxel. The SEM results also showed that there
was no poriform structure on the surface of the sustained-
release preparations after release (Fig. 8), thus it wouldn’t
affect the integrality and morphology of the preparations. So it
couldstill support thecapsular bagandprevent thecapsularbag
from shrinking after the drug was released completely.
3.5. Biocompatibility studies of P(HEMA-co-MMA)
The normal L-929 cells grew adherently and did not show
significant morphological changes when cultured with test
groups, and the viability of L-929 cells was more than 90%.tained-release preparations before and after release.
Table 3 e The growth rate of L-929 cells treated with one-
month leaching liquor of P(HEMA-co-MMA) for 2 days.
MMA/HEMA (mol:mol) Growth rate after 2d (%)
1:9 97.84
1.5:8.5 97.18
2:8 97.24
2.5:8.5 93.29
3:7 97.01
Phenol 9.11
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 2 5 2e2 6 0258While cultured with phenol, the cells floated and died and the
cell viability was only 9.11% (Table 3).
P(HEMA-co-MMA) is a kind of non-degradation material,
which has beenwidely used inmedicine, but it is still necessary
to investigate the biocompatibility of P(HEMA-co-MMA) made
by ourselves. Results showed that the test groups had a reac-
tivity grade of zero or one, and the positive control group’s
reactivity grade was four (Table 4). These indicated that the
homemade P(HEMA-co-MMA) had good biocompatibility.3.6. Studies on in-vitro pharmacodynamics
HLECs were cultured to evaluate the inhibitory effect of the
docetaxel-loaded sustained-release preparations. WhenTable 4 e Reactivity grades for elution test.
Grade Reactivity C
0 None Discrete intracytoplasmic granules; no cel
1 Slight Not more than 20% of the cells are round,
lysed cells are present
2 Mild Not more than 50% of the cells are round
empty areas between cells
3 Moderate Not more than 70% of the cell layers conta
4 Severe Nearly complete destruction of the cell lay
According to USP, the sample will meet the requirements of the test if the
reactive).
Fig. 9 e MTT analysis of cell viability after treated with docetax
HEMA ratios (n [ 3).treatedwith drug-loaded preparations, the viabilities of HLECs
were less than 20% within 20 days, especially in the first eight
days, and the viabilities of HLECs were less than 10% (Fig. 9).
These results proved that docetaxel-loaded sustained-release
preparations could inhibit HLECs proliferation for at least 20
days. And docetaxel could be released for at least one month
from these preparations in DMEM (20).
The release results of docetaxel in DMEM (20) and pH 7.4
PBS showed that the release rate of docetaxel in PBS had a
good liner correlation with that in DMEM (20). The regression
equations was y ¼ 1.2165x15.241 (MMA/HEMA ¼ 1:9,
r ¼ 0.9727 ( p < 0.01)), which indicated a positive correlation
between them.
In the in-vitro pharmacodynamics studies, the docetaxel-
loaded sustained-release preparations were immersed in the
culture solution without touching the cells. In the biocom-
patibility studies of P(HEMA-co-MMA), the results had already
shown that the polymer was non-toxic, so the anti-
proliferative agent must have been released effectively from
the polymer [44]. In the in-vitro pharmacodynamics studies,
the inhibitory effect of the docetaxel-loaded sustained-release
preparations proved to be constant and effective, especially
on the second, fourth, eighth and tenth day.
In the in-vitro drug release studies, the concentrations of
docetaxel in release media were much higher than its IC50 inonditions of all cultures
l lysis
loosely attached, and without intracytoplasmic granules; occasional
and devoid of intracytoplasmic granules; no extensive cell lysis and
in round cells or are lysed
ers
response to the Sample Preparation is not greater than grade 2 (mildly
el-loaded sustained-release preparations of different MMA/
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 2 5 2e2 6 0 259the first five days and were always higher than the IC50
(16.48 ng/ml, 72 h) of docetaxel at all times. The drug could be
released from the docetaxel-loaded sustained-release prepa-
rations stably in DMEM (20) and the release rate of docetaxel in
DMEM (20) had a positive correlation with that in PBS (pH 7.4).
According to the pathogenesis and clinical experiences, a
higher inhibitor concentration is necessary to clear LECs at the
initial stages after surgery, when the proliferation and
migration of LECs is extremely active. So it is necessary that
the drug should be quickly released from the docetaxel-loaded
sustained-release preparations and has a high inhibition rate
during the first ten days. Furthermore, PCO is unlikely to occur
if proliferation and transplant of the rudimental LECs don’t
occur. Thus, the initial burst release is beneficial for the pre-
vention of PCO. However, in-vivo pharmacodynamics studies
are still needed to prove whether the concentration of drug
can reach therapeutic levels and whether it is toxic to other
intraocular tissues.4. Conclusion
In our research, the in-vitro pharmacodynamics experiments
indicated that HLECs were sensitive to docetaxel and the
docetaxel-loaded sustained-release preparations could
maintain an effective drug concentration for up to 20 days.
Owing to the limitations that in the present studies, only in-
vitro experiments were conducted for the proposed prepara-
tion, further experiments would be conducted to study the
correlation between the in-vitro experiments and the in-vivo
experiments. This system and the preparations had very
high potential for future clinical application.
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